ORION CORPORATION PRESS RELEASE 24 OCTOBER 2026 at 9.35 EEST Darolutamide plus ADT and radiation therapy reduces risk of ...
The clinical trial “provides the clearest picture to date on how shorter radiation therapy schedules interact with modern ...
Thousands of men with high-risk prostate cancer could soon live longer, thanks to a test that helps doctors identify which ...
Prostate cancer treatments carry different risks. Dr. Fernando Bianco argues for informed decisions that balance cancer ...
A newly approved immunotherapy was effective for some forms of rectal cancer without the need for additional treatments.
What matters in prostate cancer treatment is not simply removing the cancer. How much urinary and sexual function can be ...
A multicenter study combining radiation-oncologist contouring with retrospective PSMA PET recurrence mapping found uneven ...
Surgery linked to more urinary and sexual side effects, while radiation associated with other urinary complications and higher all-cause mortality.
Promising but early immunotherapy developments in localized, high-risk prostate cancer seek to augment standard treatments ...
IF GETTING A screening test for prostate cancer isn’t on your radar, it’s probably because the government guidelines ...
Five-year results from the NRG-GU003 Phase III trial show that a 25-fraction, five-week postoperative radiation schedule ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results